Abstract
Overview focused on new aspects in renal bone disease, aiming to describe the new definition of chronic kidney disease mineral bone disorder (CKD-MBD) and to describe recent pharmacological measures (selective activators of vitamin D receptor, calcimimetics, non-calcium based phosphate binders sevelamer and lanthanum carbonate).